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Abstract
Hepatitis C Virus (HCV) genotype and viral load are two significant predictive variables knowledge of which might
persuade treatment decisions. The objective of the present study was to identify the distribution of different HCV
genotypes circulating in the study area and to estimate viral load in chronically HCV infected patients. Out of total
305 HCV positive patients, 177 (58%) were males and 128 (42%) were females. Frequency breakup of the HCV
positive patients was 169, 69, 38 and 29 from Abbottabad, Mansehra, Haripur and Battagram districts respectively.
Out of the total 305 tested serum samples, 255 (83.06%) were successfully genotyped whereas 50 (16.4%) samples
were found with unclassified genotypes. Among typable genotypes, 1a accounted for 21 (6.8%) 1b for 14 (4.6%),
2a for 4 (1.31%) 3a for 166 (54.42%) and genotype 3b for (8.19%). Twenty five (8.19%) patients were infected with
mixed HCV genotypes. Viral load distribution was classified into three categories based on its viral load levels such
as low (< 60, 0000 IU/mL), intermediate (60,0000-80,0000 IU/mL) and high (> 80,0000 IU/mL). The baseline HCV
RNA Viral load in HCV genotype 3 infected patients was 50 (26.17%), 46 (24.08%) and 95 (49.73%) for low,
intermediate and high categories respectively. For genotypes other than 3, these values for low, intermediate and
high viral load categories were 50 (43.85), 35 (30.70) and 29 (25.43) respectively. Pre-treatment viral load in patients
with untypable genotype was 19 (38.00%), 5 (20.00%) and 11 (44.00%) for low, intermediate and high viral load
categories. Viral load distribution was also categorized sex wise; for males it was 58 (32.76%), 26 (14.68%) and 93
(52.54%) whereas for females it was 40 (31.25%), 34 (26.56%) and 54 (42.18%) for low, intermediate and high viral
load respectively. In conclusion HCV genotype 3a is the most prevalent genotype circulating in Hazara Division like
other parts of pakistan. Pre-treatment viral load is significantly high (p 0.014) in patients infected with HCV
genotype 3 as compared to other genotypes.
Background
Hepatitis C virus (HCV) is a principal cause of chronic
liver diseases including liver fibrosis, liver cirrhosis and
hepatocellular carcinoma [1,2]. Nearly 170-200 million
individuals infected globally including 10-17 million per-
sons in Pakistan [1,3-5]. HCV is an enveloped virus having
positive single stranded RNA as its genome that was firstly
discovered in 1989 belonging to a virus family Flaviviridae
[3,6,7]. HCV genome is approximately 9.6 kb in length
with single open reading frame and encodes a polypeptide
of 3000 amino acids [8,9]. Total six major HCV genotypes
and multiple subtypes have been identified from around
the world [10]. Identification of HCV genotype/subtype is
extremely important clinically before prescribing therapy
because genotypes 1 & 4 show more resistance as com-
pared to genotypes 2 and 3 to PEG-IFN plus ribavarin
therapy, therefore different types of HCV genotypes
require different duration and dose of anti viral therapy
[11]. Treatment durations for genotypes 1 and 4 are 48
weeks where as for 2 and 3 is 24 weeks with PEG-IFN
plus ribavarin therapy [12]. Prevalence of viral genotypes
has been documented in three different patterns to date
[1]. First pattern differentiate by high genetic heterogeneity
involves different geographical regions of West Africa with
types 1 and 2 [13], Central Africa with type 4 [14] and
Asia with types 3 and 6 [15]. Second pattern entails
regions with a few subtypes circulating in an intravenous
drugs abusers groups, e.g., subtype 3a [16]. The last pat-
tern involves areas where a single subtype is circulate,
such as in Egypt with subtype 4a [17] and South Africa
with subtype 5a [18].
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also been shown to be prognostic indicator of response
to antiviral therapy [19] as increased pre-treatment viral
load has been linked with low rates of response to stan-
dard interferon therapy [20-22]. Several studies have
shown that patients with lower pre-treatment viral load
(< 80,0000) are more likely to positively respond to cur-
rently available antiviral therapy as compared to high
pre-treatment viral load (> 80,0000) [23-25]. The find-
ings of several studies have also been indicated that a
decline in HCV viral load during the first 2-12 weeks of
therapy with antiviral treatment indicate to be prognos-
tic of therapeutic efficacy [26,27]. Hence HCV genotype,
baseline viral load and decrease of viral load in the stage
of initial therapy play important roles in modifying and
optimizing antiviral treatment [28].
In Pakistan few large scale studies are available that have
been conducted in different districts, cities and towns for
the identification of HCV genotypes in chronic HCV
infected patients circulating in that particular areas
[5,29-31]. No study is available from Pakistan that has cor-
related pre-treatment viral load with HCV genotypes.
Therefore, this study was conducted to identify the distri-
bution of different HCV genotypes/Subtypes and pre-
treatment HCV RNA viral load in HCV infected patients
belonged to different parts of Hazara Division of Pakistan.
Methods
Sampling
Total of 305 serum samples were collected from different
chronically HCV infected patients for HCV genotyping
along with specifically designed data sheets from patients
visiting/attending various secondary and tertiary collection
centers situated in different cities/towns of Hazara Divi-
sion of Khyber Pakhtoonkhaw (KPK), Pakistan. Informed
consent was taken in written form from each participated
patient including, demographic characteristic, age, district,
and estimated time of infection along with complete
address and phone number of the patients. Written
informed consent was taken from each patient.
HCV Qualitative test
Samples were subjected firstly for the detection of HCV
RNA qualitatively as previously describe by Idrees [32].
Reverse transcription PCR (RT-PCR) was done for the
identification of HCV RNA. RNA was extracted from
100 μlp a t i e n t ’s sera using Quigen RNA extraction kit
according to the kit protocol. Nested PCR were per-
formed using Taq DNA polymerase enzyme (Fermentas
Technologies USA) in a volume of 20 μl reaction mix.
The nested PCR products were visualized on 2% agarose
gel under “UV” light using “Uvitec” gel documentation
system.
HCV Quantitative test
HCV RNA quantification was done by using SmartCycler
II Real-time PCR (Cepheid, Sunnyvale, Calif. USA) with
HCV RNA quantification kits (Sacace Biotechnologies,
Italy). The SmartCycler II system is a PCR system by
which amplification and diagnosis were accomplished at
same time with TaqMan technology (Applied Biosystems,
Foster City, Calif) using fluorescent probes to investigate
amplification after each replicating cycle. The lower and
upper detection limits of the used assay were 250 and
5.0 × 10
8 IU/mL, respectively. Specimens yielding values
above the upper limit were diluted 100-fold, retested and
the obtained values were multiplied by this dilution fac-
tor to get the actual HCV RNA concentration in interna-
tional units (IU) per mL.
HCV Genotyping
A l lq u a l i t a t i v eP C Rp o s i t i v es e r aw e r es u b j e c t e dt oH C V
genotyping by using type-specific HCV genotyping proce-
dure as described previously in detail [33]. Briefly, 10 μl
(about 50 ng) of HCV RNA was reverse transcribed to
cDNA using 100 U of M-MLV RTEs at temperature of
37°C for 50 minutes. Two μl of synthesized cDNA was
used for PCR amplification of 470-bp region from HCV
5’NCR along with core region by first round PCR amplifi-
cation. The amplified first round PCR product were sub-
jected to two second rounds of nested PCR amplifications.
One with mix-I primers set and the second with mix-II
primers set in a reaction volume of 10 μl. Mix-I had speci-
fic genotype primers set for 1a, 1b, 1c, 3a, 3c and 4 geno-
types and mix-II contain specific genotype primers set for
2a, 2c, 3b, 5a and 6a.
Statistical Analysis
Given data was analyzed and the summary statistic was
carried out by a statistical package, SPSS version 10.0. All
variables results were given in the form of rates (%). Chi
Square test was used for categorical variables that mea-
sured association among categorical variables. All data are
presented as mean values or number of patients. P-values
less than 0.05 were considered significant
Results
Distribution of HCV genotypes in studied patients
Table 1 shows the distribution of HCV genotypes in the
studied population. Out of total 305 patients, more than
88% were male and about 42% were female. Out of the
total 305 tested serum samples, type-specific PCR frag-
ments were seen in 255 (83.06%) serum samples whereas
50 (16.4%) samples were found with untypeable genotypes
as no genotype-specific band was seen in these samples.
The distribution of typeable genotypes is as follows: geno-
type 1a accounted for 21 (6.8%), 1b for 14 (4.6%), 2a for
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Page 2 of 64 (1.31%) 3a for 166 (54.42%) and genotype 3b for 25
(8.19%) patients. Twenty five (8.19%) patients were
infected by two (mixed) genotypes at a time. Predominant
genotype of the study is 3a followed by 3b. The predomi-
nant genotype among males was 3 (61.58%), followed gen-
otype 1 (11.86%), 2 (1.69%), mixed genotype (8.47%) and
undetermined (16.38%). Similarly the frequent genotype
among the infected female patients was 3 (64.06%) fol-
lowed genotype 1 (10.39%), genotype 2 (0.78), (16.40%)
and mixed genotypes (7.81%). The HCV sub-genotype pat-
tern in males was: subtype 3a was identified in 96
(54.23%), 3b in 12 (9.37%), 1a in 11 (6.21%), 1b in 10
(5.64%) and 2a in 3 (1.69%) HCV infected patients.
Among the females it was: subtype 3a in 70 (54.68%), 3b
in 12 (9.37%), 1a in 10 (7.8%), 1b in 4 (3.12%) and 2a was
identified in 1 (0.78%) patient.
Distribution of HCV genotypes in different age groups
The distribution of HCV genotypes in different age group
patients is shown in table 2. Genotype 3a was the predo-
minant genotype (45.8%) in young patients (ages between
31-40 years). Frequent prevalence was found in age group
of 31-40
Distribution of HCV genotypes in different parts of
Hazara
Table 3 demonstrates the prevalence of HCV genotypes
that were recorded from HCV patients belonged to differ-
ent parts of Hazara Division. Among the typeble geno-
types 169 belonged to Abbottabad. Among the genotypes
samples from Abbottabad 12 (7.10%) were 1a, 10 (5.10%)
were 1b, 100 (59.17%) were 3a, 12 (7.10%) were untypable
and 26 (15.38%) were with mixed genotypes. Genotypes
distribution among the patients of Mansehra was 69.
Among these, 4 (5.79%) were 1a, 2 (2.8%) were 1b, 40
(57.97%) were 3a, 10 (3.55%) were 3b and 8 (11.59%) were
with mixed genotypes. Five (7.24%) were untypeable. Out
of 38 samples that were genotyped in HCV positive sera
from Haripur, 3 (7.89%) were 1a, 18 (47.36%) were 3a,
4 (10.52%) were 3b, 8 (21.05%) were with mixed genotypes
and 3 (7.89%) were undetermined. Prevalence of HCV
genotypes among Battagram positive patients were 29 in
which 2 (6.89%) were 1a, 1 (3.44%) was 2a, 8 (27.58%)
were 3a, 5 (17.24%) were 3b, 8 (27.58%) were with double
infection and 5 (17.24%) were unclassified HCV.
HCV RNA viral loads in male and female patients with
different genotypes
Viral load was classified into three categories based on its
level such as low (< 60, 0000 IU/ml), intermediate
(60,0000-80,00000 IU/ml) and high (> 80,00000 IU/ml)
viral load. Base line HCV Viral load for each genotype in
both male and female patients are shown in table 4. Pre-
treatment viral load was found high significantly (p 0.014)
in patients infected with HCV genotype 3 as compared to
other genotypes. No significant difference was observed in
male and female HCV infected patients (p 0.343).
Discussion
Hazara Division is a historical and beautiful locality of the
province Khyber Pakhtoonkhaw (KPK) province of Paki-
stan. This part of the world has been mapped such that on
the North and East lies the Northern Areas and Azad
Kashmir, to the South are the Islamabad Capital Territory
and the province of Punjab, while the rest of KPK lies to
its West. The river forms majority of the western border
of the Division by running in a North-south fashion.
Hazara Division is one of the most diverse regions based
on the ethnic groups it is comprised of, such as Awan,
Dhund Abbassi, Gabari, Ghakkar, Gujjar, Jadoon, Karlal,
Karlugh, Kohistanis, Maddakhel, Mishawani, Paracha,
Shilmani, Syed, Swati, Tahirkheli, Tanoli, Tareen, Turks,
Kashmiri, Dilazak and the Isazai Pashtoon respectively
[34].
In this study we have studied the distribution of HCV
genotypes and associated these genotypes with gender. The
results of this study clearly showed that there is no varia-
tion among the HCV genotypes and gender as different
HCV genotypes were distributed with same ratio between
males and females. In agreement with this observation of
our study, no significant difference was seen by Idrees and
Riazuddin [5] in gender and variation among genotypes in
this part of the world. On the other hand in contrast to
our observation, in Libya HCV genotypes were not distrib-
uted with same pattern between males and females as seen
in Pakistan. In Libya, the prevalence of HCV genotype 1
was found to be significantly associated with males while
genotype 4 was seen frequently in females [35]. Our results
indicated that high prevalence rate 40.32% of HCV infec-
tion was found between age group of 30-40. These findings
are in agreement with the findings of Ahmad et al,[ 2 9 ]
Table 1 Pattern of HCV genotype among the infected
patients (N = 305)
Genotype Subtype Male (%) Female (%) Total (%)
Genotype 1 21 (11.86%) 14 (10.93%) 35 (11.47%)
1a 11 (6.21%) 10 (7.8%) 21 (6%)
1b 10 (5.64%) 4 (3.12%) 14 (4%)
Genotype 2 3 (1.69%) 1 (0.78%) 4 (1.31%)
2a 3 (1.69%) 1 (0.78%) 4 (1.31%)
Genotype 3 109 (61.58%) 82 (64.06%) 191 (62.62%)
3a 96 (54.23%) 70 (54.68%) 166 (86.91%)
3b 13 (7.34%) 12 (9.37%) 25 (13.08%)
Mixed Genotypes 15 (8.47%) 10 (7.81%) 25 (8.19%)
Unclassified 29 (16.38%) 21 (16.40%) 50 (16.39%)
Total 177 128 305
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of ≤ 40 years and similar findings were also observed by
Inamullah et al, [30]. But our findings contradict from that
of Muhammad et al, [36] that high HCV prevalence rate in
Pakistan was found in old age group people. So these
results suggest that early diagnosis of HCV might be due
to the awareness of public about HCV infection in this part
of the world. Currently a number of studies have been car-
ried out to find the frequencies of various HCV genotypes
in different geographical regions of Pakistan and the most
prevalent genotype was 3a [5,28,31,37]. Data analysis of the
present study showed that genotype 3a (54.42%) has high
prevalence rate followed by 3b and 1a in chronic HCV
infected patients. These results confirmed the findings of
other studies reported from Pakistan that the most preva-
lent genotype is 3a followed by genotype 3b and 1a, respec-
tively [27,6,5,33,38]. Identified HCV genotypes in our study
showed no regional difference and was distributed with
same fashion predominant genotype was 3a followed by 3b
as has also been reported by Ali et al., [27] from various
regions of Pakistan where the authors concluded that there
is no regional difference in HCV genotype distribution.
Our pattern of HCV genotypes distribution is similar to
that reported from neighboring countries like in Iran and
India where predominant genotype is 3 [39,40], and is dif-
ferent from South Asian countries such as Japan and Thai-
land where genotype 1 is the common HCV genotype
[41,42].
In the present study 8.19% of the studied patients were
found infected by two different genotypes at the same
time, majority of these were thalassaemic patients who
had received unsafe blood in past. Our results are sup-
ported by other studies that show that mixed genotypes
are more frequent where blood transfusion is common
especially in thalassaemic patients [27]. Franciscus [21]
states that mixed genotypes in a single patient may affect
the antiviral therapy response and disease succession. We
were unable to identify HCV genotypes 4, 5 and 6 in the
current study. This observation confirmed the previously
reported arguments that these three genotypes are not
existing in this region or these are partially absent from
Pakistan [27,28].
It has already been reported that patients with higher
viral load show lower response rates to standard antiviral
therapy as compared to patients having lower viral load
[21]. Our findings carry some important implication for
the therapeutic hindrance that genotype 3 is the most
common genotype in Pakistan [5] and also in our studied
patients. Untimely detection and treatment are significant
to achieve a high level of sustained virological response
(SVR) [43]. Early time detection involves the identifica-
tion of low HCV RNA level [11]. As determined by Von
et al., [21] and Dalgard et al, [22], that shorter therapy
schedules told that genotype 3 HCV infected patients
with low baseline viral load (HCV-RNA, < 600, 000-800,
000 IU/mL) had more likely to attained a sustained
Table 2 Pattern of HCV genotypes/subtypes in different age groups (N = 305)
Age groups (in years)
Genotype/Subtype 10-20 21-30 31-40 41-50 51-60 > 60
1a 0 8 (38.08%) 3 (14.3%) 8 (38.08%) 2 (9.0%) 0
1b 0 3 (21.42%) 7 (50%) 2 (14.5%) 2 (14.5%) 0
2a 1 (25%) 1 (25%) 1 (25%) 0 1(25%) 0
3a 2 (1.2%) 33 (19.9%) 76 (45.8%) 32 (19.3%) 15 (9.03%) 8 (4.81%)
3b 2 (8%) 8 (32%) 7 (28%) 6(24%) 1 (4%) 1 (4%)
Mixed genotypes 4 (16%) 4 (16%) 8 (32%) 5 (20%) 3 (12%) 1(4%)
Unclassified 7 (28%) 7 (28%) 21 (24%) 8 (16%) 6 (12%) 1(2%)
Total 16 (5.25%) 64 (20.32%) 123(40.32%) 61(20%) 30(9.83%) 11 (3.61%)
Table 3 Prevalence of HCV genotypes in different geographic regions of Hazara (N = 305)
Genotype Sub-type Isolated from Abbottabad Isolated from Mansehra Isolated from Haripur Isolated from Battagram P Value
1 1a 12(7.10%) 4(5.79%) 3(7.89%) 2(6.89%) NS
1b 10(5.90%) 2(2.8%) 2(5.26%) 0(0.00%) NS
2 2a 3(1.77%) 0(0.00%) 0(0.00%) 1(3.44%) NS
3 3a 100(59.17%) 40(57.97%) 18(47.36%) 8(27.58%) NS
3b 6(3.55%) 10(14.49%) 4(10.52%) 5(17.24%) < 0.05
Mixed _ 26(15.38%) 8(11.59%) 8(21.05%) 8(27.58%) 0.05
Unclassified _ 12(7.10%) 5(7.24%) 3(7.89%) 5(17.24%) > 0.05
Total 169 69 38 29
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high viral load (HCV-RNA > 60000-800000 IU/mL). We
found only 50 (26.17%) patients infected by genotype 3 in
our studied patients that had intermediate viral load
(< 80,0000) after HCV RNA quantification. As per the
research findings Von et al. [21], patients having geno-
type 3 and with high viral load (> 80,0000 IU/mL) should
be treated for 24 weeks where as patients with low
(< 80,0000 IU/mL) RNA viral load might be treated for
16 weeks for those patients whose HCV RNA PCR is
undetectable at week 4 of treatment. Our findings along
with those of Von et al. [21] further recommend that
extensive information about HCV genotype and basal
RNA viral load is necessary when planning therapy stra-
tegies against HCV at national level. These results also
help to modify antiviral therapy individually for infected
HCV patients with genotype 3 that will reduce economic
burden, side effects of antiviral therapy, and also may
promote optimize response rates. Finally the results of
this study show that more than one genotype of HCV cir-
culates in Hazara Division of KPK, Pakistan. Pre domi-
nant genotype was 3a followed by 3b and 1a.
Conclusions
In the present study, we conclude that HCV genotype
3a is the most prevalent genotype circulating in this
region of the world. Regional difference do exists in
HCV genotypes. Majority of the infected patients are
young ages between 31-40 years. Baseline viral load is
significantly high in patients infected by HCV genotype
3 (subtypes a & b) as compared to other genotypes such
as 1 (subtypes a, b, c), 2 (subtypes a, b) and untypeable
genotypes.
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